Invesco Ltd. Acquires 550,246 Shares of Cencora, Inc. (NYSE:COR)

Invesco Ltd. lifted its holdings in Cencora, Inc. (NYSE:COR) by 20.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,243,531 shares of the company’s stock after acquiring an additional 550,246 shares during the quarter. Invesco Ltd. owned 1.68% of Cencora worth $728,757,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in COR. JFS Wealth Advisors LLC boosted its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of Cencora in the 4th quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after acquiring an additional 69 shares during the period. Kentucky Trust Co bought a new position in Cencora during the 4th quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co increased its stake in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by corporate insiders.

Cencora Trading Down 1.4 %

Shares of COR opened at $274.60 on Tuesday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm’s 50-day moving average price is $257.67 and its 200-day moving average price is $243.14. The firm has a market capitalization of $53.25 billion, a price-to-earnings ratio of 39.06, a PEG ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.80%. Cencora’s payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on COR. JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Finally, Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $280.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.